• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis.

作者信息

Boons Eline, Nogueira Tatiane C, Dierckx Tim, Menezes Soraya Maria, Jacquemyn Maarten, Tamir Sharon, Landesman Yosef, Farré Lourdes, Bittencourt Achiléa, Kataoka Keisuke, Ogawa Seishi, Snoeck Robert, Andrei Graciela, Van Weyenbergh Johan, Daelemans Dirk

机构信息

KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, B-3000, Leuven, Belgium.

KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical and Epidemiological Virology, Rega Institute, B-3000, Leuven, Belgium.

出版信息

Blood Cancer J. 2021 Feb 1;11(2):27. doi: 10.1038/s41408-021-00409-3.

DOI:10.1038/s41408-021-00409-3
PMID:33563902
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7873181/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f94a/7873181/d94ba6c7c6f7/41408_2021_409_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f94a/7873181/88b97420d5e9/41408_2021_409_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f94a/7873181/d94ba6c7c6f7/41408_2021_409_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f94a/7873181/88b97420d5e9/41408_2021_409_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f94a/7873181/d94ba6c7c6f7/41408_2021_409_Fig2_HTML.jpg

相似文献

1
XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis.XPO1抑制剂是成人T细胞白血病的一种新型治疗选择，可引发p53介导的半胱天冬酶依赖性凋亡。
Blood Cancer J. 2021 Feb 1;11(2):27. doi: 10.1038/s41408-021-00409-3.
2
Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.XPO1/CRM1介导的核输出选择性抑制剂在弥漫性恶性腹膜间皮瘤中的抗肿瘤活性：生存素的作用
Oncotarget. 2015 May 30;6(15):13119-32. doi: 10.18632/oncotarget.3761.
3
XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.使用KPT-330阻断XPO1通过激活p53-p21和p27途径促进皮肤T细胞淋巴瘤细胞凋亡。
Sci Rep. 2024 Apr 23;14(1):9305. doi: 10.1038/s41598-024-59994-5.
4
KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.XPO1 介导的核输出抑制剂 KPT-330 在肝细胞癌中具有抗增殖活性。
Cancer Chemother Pharmacol. 2014 Sep;74(3):487-95. doi: 10.1007/s00280-014-2495-8. Epub 2014 Jul 17.
5
Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.XPO1抑制在胸腺上皮肿瘤中的治疗作用
Cancer Res. 2017 Oct 15;77(20):5614-5627. doi: 10.1158/0008-5472.CAN-17-1323. Epub 2017 Aug 17.
6
XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis.XPO1 抑制剂 KPT-330 通过干扰 rRNA 加工和 Mcl-1 蛋白合成与 Bcl-xL 抑制剂协同诱导癌细胞凋亡。
Cell Death Dis. 2019 May 21;10(6):395. doi: 10.1038/s41419-019-1627-9.
7
Chemoproteomic Profiling of Covalent XPO1 Inhibitors to Assess Target Engagement and Selectivity.共价XPO1抑制剂的化学蛋白质组学分析以评估靶点结合和选择性
Chembiochem. 2021 Jun 15;22(12):2116-2123. doi: 10.1002/cbic.202100038. Epub 2021 Apr 22.
8
Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.核输出选择性抑制剂（SINE）化合物的抗肿瘤活性，在非霍奇金淋巴瘤中通过与mTOR抑制剂及地塞米松联合使用而增强。
Cancer Lett. 2016 Dec 28;383(2):309-317. doi: 10.1016/j.canlet.2016.09.016. Epub 2016 Sep 28.
9
Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.核输出选择性抑制剂（SINE）XPO1拮抗剂KPT-185对核糖体生物合成和翻译通量的抑制作用
PLoS One. 2015 Sep 4;10(9):e0137210. doi: 10.1371/journal.pone.0137210. eCollection 2015.
10
Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing.通过CRISPR/Cas9基因组编辑鉴定小分子CRM1/XPO1抑制剂的药物靶点选择性
Chem Biol. 2015 Jan 22;22(1):107-16. doi: 10.1016/j.chembiol.2014.11.015. Epub 2015 Jan 8.

引用本文的文献

1
Selinexor's Immunomodulatory Impact in Advancing Multiple Myeloma Treatment.塞利尼索在推进多发性骨髓瘤治疗中的免疫调节作用。
Cells. 2025 Mar 13;14(6):430. doi: 10.3390/cells14060430.
2
Distinctive genomic features of human T-lymphotropic virus type 1-related adult T-cell leukemia-lymphoma in Western populations.西方人群中与1型人类嗜T淋巴细胞病毒相关的成人T细胞白血病-淋巴瘤的独特基因组特征。
Haematologica. 2024 Dec 1;109(12):4021-4039. doi: 10.3324/haematol.2024.285233.
3
XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.

本文引用的文献

1
Interferon regulatory factor 4 as a therapeutic target in adult T-cell leukemia lymphoma.干扰素调节因子 4 作为成人 T 细胞白血病淋巴瘤的治疗靶点。
Retrovirology. 2020 Aug 28;17(1):27. doi: 10.1186/s12977-020-00535-z.
2
Decreased RORC expression and downstream signaling in HTLV-1-associated adult T-cell lymphoma/leukemia uncovers an antiproliferative IL17 link: A potential target for immunotherapy?HTLV-1 相关成人 T 细胞淋巴瘤/白血病中 RORC 表达和下游信号的降低揭示了一种抗增殖的 IL17 关联：免疫治疗的潜在靶点？
Int J Cancer. 2019 Apr 1;144(7):1664-1675. doi: 10.1002/ijc.31922. Epub 2018 Dec 18.
3
A genetic IFN/STAT1/FAS axis determines CD4 T stem cell memory levels and apoptosis in healthy controls and Adult T-cell Leukemia patients.
使用KPT-330阻断XPO1通过激活p53-p21和p27途径促进皮肤T细胞淋巴瘤细胞凋亡。
Sci Rep. 2024 Apr 23;14(1):9305. doi: 10.1038/s41598-024-59994-5.
4
Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53/mTOR pathway.XPO1 抑制剂 KPT-330 通过激活 p53/mTOR 通路诱导胆囊癌细胞发生自噬依赖性凋亡。
J Transl Med. 2022 Sep 30;20(1):434. doi: 10.1186/s12967-022-03635-w.
5
Anti-Osteoclast Effect of Exportin-1 Inhibitor Eltanexor on Osteoporosis Depends on Nuclear Accumulation of IκBα-NF-κB p65 Complex.核输出蛋白1抑制剂埃坦色诺对骨质疏松症的抗破骨细胞作用取决于IκBα-NF-κB p65复合物的核内蓄积
Front Pharmacol. 2022 Aug 30;13:896108. doi: 10.3389/fphar.2022.896108. eCollection 2022.
一种遗传的IFN/STAT1/FAS轴决定了健康对照者和成人T细胞白血病患者中CD4 T干细胞记忆水平和细胞凋亡情况。
Oncoimmunology. 2018 Feb 13;7(5):e1426423. doi: 10.1080/2162402X.2018.1426423. eCollection 2018.
4
HTLV Deregulation of the NF-κB Pathway: An Update on Tax and Antisense Proteins Role.人嗜T淋巴细胞病毒对核因子κB信号通路的失调作用：Tax蛋白和反义蛋白作用的最新进展
Front Microbiol. 2018 Feb 21;9:285. doi: 10.3389/fmicb.2018.00285. eCollection 2018.
5
IFN-β induces greater antiproliferative and proapoptotic effects and increased p53 signaling compared with IFN-α in PBMCs of Adult T-cell Leukemia/Lymphoma patients.与干扰素-α相比，干扰素-β在成人T细胞白血病/淋巴瘤患者的外周血单个核细胞中诱导出更强的抗增殖和促凋亡作用，并增强了p53信号传导。
Blood Cancer J. 2017 Jan 27;7(1):e519. doi: 10.1038/bcj.2016.126.
6
Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1-infected T cells.成人T细胞白血病：人嗜T淋巴细胞病毒1型感染的T细胞克隆性扩增和转化的分子基础
Blood. 2017 Mar 2;129(9):1071-1081. doi: 10.1182/blood-2016-09-692574. Epub 2017 Jan 23.
7
Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma.人类输出蛋白1是HIV与艾滋病相关淋巴瘤联合治疗的靶点。
EBioMedicine. 2015 Aug 1;2(9):1102-13. doi: 10.1016/j.ebiom.2015.07.041. eCollection 2015 Sep.
8
Integrated molecular analysis of adult T cell leukemia/lymphoma.成人 T 细胞白血病/淋巴瘤的综合分子分析。
Nat Genet. 2015 Nov;47(11):1304-15. doi: 10.1038/ng.3415. Epub 2015 Oct 5.
9
Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing.通过CRISPR/Cas9基因组编辑鉴定小分子CRM1/XPO1抑制剂的药物靶点选择性
Chem Biol. 2015 Jan 22;22(1):107-16. doi: 10.1016/j.chembiol.2014.11.015. Epub 2015 Jan 8.
10
Interferon-α (IFN-α) suppresses HTLV-1 gene expression and cell cycling, while IFN-α combined with zidovudine induces p53 signaling and apoptosis in HTLV-1-infected cells.干扰素-α（IFN-α）抑制 HTLV-1 基因表达和细胞周期，而 IFN-α 与齐多夫定联合使用可诱导 HTLV-1 感染细胞中的 p53 信号转导和凋亡。
Retrovirology. 2013 May 20;10:52. doi: 10.1186/1742-4690-10-52.